SARS-CoV 2 Omicron prevalent in vaccine breakthrough cases in Bahia, Brazil

In a recent study posted to the medRxiv* pre-print server, researchers performed genomic monitoring to estimate the magnitude and range of the different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) in SARS-CoV-2 reinfection cases among fully vaccinated individuals in Salvador, Bahia, Brazil.

Study: Genomic monitoring unveils a high prevalence of SARS-CoV 2 Omicron Variant in vaccine breakthrough cases in Bahia, Brazil. Image Credit: haidaralf/Shutterstock

Study: Genomic monitoring unveils a high prevalence of SARS-CoV 2 Omicron Variant in vaccine breakthrough cases in Bahia, Brazil. Image Credit: haidaralf/Shutterstock

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Globally, several World Health Organization (WHO)-approved coronavirus disease 2019 (COVID-19) vaccines are available that are highly potent in preventing COVID-19. Simultaneously, new SARS-CoV-2 VOCs continue to emerge, primarily in countries where vaccine coverage is low. Recently, SARS-CoV-2's new VOC Omicron post-emerging in South Africa, being much more aggressive than its predecessor Delta variant, spread worldwide quickly. Additionally, studies have evidenced that it caused incessant breakthrough infections (BTIs) even among vaccinated individuals globally.

Moreover, even if a vaccinated individual has a favorable prognosis and significantly reduced COVID-19-related morbidity and mortality, they may become a possible viral carrier and trigger viral dissemination within the community.

About the study

In the present study, researchers screened 29 fully vaccinated (with two vaccine doses) individuals irrespective of their age and gender in the state of Bahia who contracted reinfection and remained asymptomatic or developed symptoms during the course of the disease.

They gathered the oropharyngeal and nasal swabs of all the 29 study participants at the Laboratory of Virology at the Federal University of Bahia. There were also four 7- and 11-year-olds who were unvaccinated.

They detected SARS-CoV-2 using a quantitative reverse transcriptase-polymerase chain reaction (RT-qPCR) assay. The researchers filtered out samples with cycle threshold (Ct) values of ≤30 and subjected those to viral genomic sequencing using Nanopore technology. Running negative control samples helped filter out any possible sample contamination with less than 2% mean coverage.

The researchers performed all the study experiments in a biosafety level-2 (BSL-2) cabinet. They used a superscript IV reverse transcriptase kit for complementary DNA (cDNA) synthesis; subsequently, cDNA was subjected to multiplex polymerase chain reaction (PCR) sequencing using the Q5 High Fidelity Hot-Start DNA Polymerase and a set of specific primers.

The newly identified SARS-CoV-2 isolates were assigned a lineage using the Pangolin-lineage classification software. Subsequently, these isolates were mapped to a pool of 3,441 genomes, collected worldwide up to October 28th, 2021, to draw phylogenetic inferences.

Study findings

The self-reported COVID-19 symptoms of the study participants ranged from asymptomatic to mild, and their RT-qPCR Ct values varied between 14.6 and 27.2, even in individuals who declared themselves asymptomatic.

Genomic epidemiology of the SARS‐CoV‐2. Omicron variant in Salvador, Bahia, Northeast Brazil. A) Dynamics of the SARS-CoV-2 epidemic in Bahia showing the progression in the proportion of circulating variants in the state over time, with the rapid replacement of the Delta by the Omicron variant; B) Time-resolved maximum likelihood phylogenetic tree including the newly (n=29) Omicron isolates obtained in this study plus n = 4,249 representative SARS‐CoV‐2 genomes collected up to January 16th, 2021. Alpha, Beta, Gamma, Delta and Omicron VOCs are highlighted in the tree. Newly Omicron and Delta genomes obtained in this study are highlighted with a red border. Genomes of other lineages are showed in grey.

Genomic epidemiology of the SARS‐CoV‐2. Omicron variant in Salvador, Bahia, Northeast Brazil. A) Dynamics of the SARS-CoV-2 epidemic in Bahia showing the progression in the proportion of circulating variants in the state over time, with the rapid replacement of the Delta by the Omicron variant; B) Time-resolved maximum likelihood phylogenetic tree including the newly (n=29) Omicron isolates obtained in this study plus n = 4,249 representative SARS‐CoV‐2 genomes collected up to January 16th, 2021. Alpha, Beta, Gamma, Delta and Omicron VOCs are highlighted in the tree. Newly Omicron and Delta genomes obtained in this study are highlighted with a red border. Genomes of other lineages are shown in grey.

Among the vaccinated participants, the analysis revealed that 99% of cases were due to Omicron and the Delta variant was responsible for just one COVID-19-case. Among unvaccinated individuals, all four participants were Omicron infected.

In Bahia, three VOCs primarily dominated the epidemiology, as revealed by the genomic surveillance analysis. The Gamma variant (P.1) dominated in Bahia until August 2021, before being replaced by Delta (B.1.617.2); finally, Omicron replaced the Delta variant to become the predominant variant in Bahia in December 2021. Although present, the SARS-CoV-2 Alpha variant remained at a frequency of less than 1% in Bahia.

The researchers constructed a phylogenetic tree with these VOCs to map them to those found in other parts of the world; additionally, explore the relationship between the sequenced genomes. The results of the time-sampled phylogeny revealed that the Omicron was independently introduced multiple times over time in Bahia.

Conclusions 

To summarize, the study findings suggested that fully vaccinated patients had a favorable clinical prognosis; however, they become SARS-CoV-2 carriers after a BTI within the community. In the case of Bahia, even double or triple vaccinated individuals developed BTIs from Omicron VOC with a high viral load.

The genome-wide sequencing in the state of Bahia reinforced the notion that viral dissemination generally follows national and international patterns of human mobility, facilitating the spread of emerging VOCs within countries and globally. As of 2020, the co-circulation of three different VOCs such as Gamma (P.1), Delta, and Omicron appeared to have dominated the epidemiological history in the state.

The study puts the notion that herd immunity of over 70% prevents the population-level dissemination of SARS-CoV-2 under scrutiny as Brazil is among those countries that have surpassed this figure. Moreover, Brazil has a relatively high COVID-19 vaccination coverage of 74.9% (with two doses of vaccine). Yet the SARS-CoV-2 reinfection rates, post-emergence of Omicron, were substantially high in Bahia.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • May 12 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Neha Mathur

Written by

Neha Mathur

Neha is a digital marketing professional based in Gurugram, India. She has a Master’s degree from the University of Rajasthan with a specialization in Biotechnology in 2008. She has experience in pre-clinical research as part of her research project in The Department of Toxicology at the prestigious Central Drug Research Institute (CDRI), Lucknow, India. She also holds a certification in C++ programming.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mathur, Neha. (2023, May 12). SARS-CoV 2 Omicron prevalent in vaccine breakthrough cases in Bahia, Brazil. News-Medical. Retrieved on November 22, 2024 from https://www.news-medical.net/news/20220223/SARS-CoV-2-Omicron-prevalent-in-vaccine-breakthrough-cases-in-Bahia-Brazil.aspx.

  • MLA

    Mathur, Neha. "SARS-CoV 2 Omicron prevalent in vaccine breakthrough cases in Bahia, Brazil". News-Medical. 22 November 2024. <https://www.news-medical.net/news/20220223/SARS-CoV-2-Omicron-prevalent-in-vaccine-breakthrough-cases-in-Bahia-Brazil.aspx>.

  • Chicago

    Mathur, Neha. "SARS-CoV 2 Omicron prevalent in vaccine breakthrough cases in Bahia, Brazil". News-Medical. https://www.news-medical.net/news/20220223/SARS-CoV-2-Omicron-prevalent-in-vaccine-breakthrough-cases-in-Bahia-Brazil.aspx. (accessed November 22, 2024).

  • Harvard

    Mathur, Neha. 2023. SARS-CoV 2 Omicron prevalent in vaccine breakthrough cases in Bahia, Brazil. News-Medical, viewed 22 November 2024, https://www.news-medical.net/news/20220223/SARS-CoV-2-Omicron-prevalent-in-vaccine-breakthrough-cases-in-Bahia-Brazil.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Phase 2 study evaluates safety and efficacy of asunercept in COVID-19 patients